PD-L1 was further analyzed by categorizing the patients based on the percentage of tumor cells expressing PD-L1 with the following results (Supplementary Table 7): strong PD-L1 expressors (expression in 50–100% of tumor cells, n = 4) compared to weak and moderate (1–49%, n = 24) and negative cases (0% n = 257) displayed borderline insignificantly shorter 5-year OS (rmean = 3.910 vs. 3.446 vs. 2.148 years, respectively, p = 0.062, Fig. 4a) and significantly shorter 10-year OS (rmean = 2.641 vs. 6.033 vs. 6.670 years, respectively, p = 0.01). The gene discussed is CD274; the disease is neoplasm.